Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty

European Journal of Endocrinology

Volumn 141, Issue 2, 1999, Pages 140-144

  Arrigo, Teresa ^a   Cisternino, Mariangela ^b   Galluzzi, Fiorella ^c   Bertelloni, Silvano ^d   Pasquino, Anna Maria ^e   Antoniazzi, Franco ^f   Borrelli, Patrizia ^g   Crisafulli, Giuseppe ^a   Wasniewska, Malgorzata ^a   De Luca, Filippo ^a,h  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; TRIPTORELIN;

ARTICLE; BODY HEIGHT; BONE AGE; CHILD; CHILD GROWTH; FEMALE; HUMAN; IDIOPATHIC DISEASE; INFANT; MAJOR CLINICAL STUDY; ONSET AGE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LUTEOLYTIC AGENTS; PUBERTY, PRECOCIOUS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPTORELIN;

EID: 0032807461     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410140     Document Type: Article

References (21)

1. Kletter GB & Kelch RP. Effect of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. Journal of Clinical Endocrinology and Metabolism 1994 79 331-334.
2. Lee PA. Advances in the management of precocious puberty. Clinical Pediatrics 1994 33 54-61.
3. Shankar RR & Pescovitz OH. Precocious puberty. Advances in Endocrinology and Metabolism 1995 6 55-89.
4. Kauli R, Kornreigh L & Laron Z. Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-Trp-6-LHRH. Hormone Research 1990 33 11-17.
5. Boepple PA, Mansfield MJ, Crawford JD, Crigler JF Jr, Blizzard RM & Crowley WF Jr. Final heights in girls with central precocious puberty following GnRH agonist-induced pituitary-gonadal suppression. Pediatric Research 1991 29 74A.
6. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S & Cutler GB. Adult height in precocious puberty after long-term treatment with deslorelin. Journal of Clinical Endocrinology and Metabolism 1991 73 1235-1240.
7. Sempe M, Pedron G & Roy-Pernot MP. Auxologie, Methode et Sequences. Paris: Theraplix, 1997.
8. Greulich WW & Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, edn 2. Stanford, CA: Stanford University Press, 1995.
9. Bayley N & Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. Journal of Pediatrics 1952 40 423-441.
10. Tanner JM, Goldstein H & Whitehouse RH. Standards for children's heights at age 2-9 years allowing for height of parents. Archives of Disease in Childhood 1970 45 755-762.
11. Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S & Cutler GB Jr. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatrica 1993 388 (Suppl) 62-68.
12. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G & Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and flnal height in females. European Journal of Pediatrics 1998 157 363-367.
13. Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatrica 1994 83 1052-1056.
14. Brauner R, Adan L, Malandry F & Zantleifer D. Adult height in girls with idiopathic true precocious puberty. Journal of Clinical Endocrinology and Metabolism 1994 79 415-420.
15. Paul D, Conte FA, Grumbach MM & Kaplan SL. Long term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. Journal of Clinical Endocrinology and Metabolism 1995 80 546-551.
16. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwè C et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Archives of Disease in Childhood 1996 75 292-297.
17. Sippell WG, Partsch CJ, Hummelink R & Lorenzen F. Langzeit-therapie mit dem retard-LHRH-agonisten Decapeptyl-Depot bei Madchen mit Pubertas praecox vera. Gynakologe 1991 21 108-113.
18. Hummelink R, Oostdijk W, Partsch CJ, Odink RJ, Drop SL & Sippell WG. Growth, bone maturation, and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl Depot in children with central precocious puberty. Hormone and Metabolic Research 1992 24 122-126.
19. Galluzzi F, Salti R, Bindi G, Pasquini E & La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatrica 1998 87 521-527.
20. Ohyama K, Tanaka T, Tachibana K, Niimi H & Fujieda K. Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. TAP-144SR CPP Study Group. Endocrinological Journal 1998 45 351-356.
21. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A & Laron Z. Final height in girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. Hormone Research 1997 47 54-61.